- A near-term opportunity in hepatitis D virus (HDV) infection with lead asset lonafarnib supports valuation 6x higher than current share price, supported by a recent acquisition in the HDV space.
- The recent approval of lonafarnib in ultra-orphan indication demonstrates Eiger’s ability to develop and commercialize a product and its existing relationship with a potential acquirer.
- Additional pipeline opportunities not included in the valuation reduce the risk, and offer combined multibillion-dollar commercial opportunity further down the line.
For further details see:
Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon